The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

The leadership change comes at the end of a week in which the California-based toymaker landed squarely in the crosshairs of ...

(NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

Shares of Kenvue rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported ...

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

The stock's rise snapped a three-day losing streak.

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSofya Tsinis - Head of Investor RelationsThibaut ...

Kenvue is the world’s largest pure-play consumer health company by revenue, generating $15 billion in annual sales. The former consumer segment of Johnson & Johnson spun off and went public in ...

May 8 (Reuters) - Kenvue (KVUE.N), opens new tab on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a $150 million impact from ...

Kenvue KVUE1.58%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...